Prestige Brands Expects OTC Assets Will Shake Loose From M&A Activity
This article was originally published in The Tan Sheet
“If you looked at it based on history,” consolidation has created opportunities to acquire OTC brands, says Prestige Brands CEO Matthew Mannelly. The firm’s interest in adding brands is “stronger than ever,” he adds.
You may also be interested in...
In Brief: Prestige Buys Insight, Quarterly Earnings For MJN And Colgate, Bio-Recovery Warned On Claims
Prestige acquires Insight Pharmaceuticals; Product relaunches boost Novartis’ consumer sales; Colgate’s N.A. sales inch up; Mead Johnson sales up 7%; and Bio-Recovery makes drug claims.
Genomma drops its unsolicited offer because it was unwilling to meet Prestige’s demand for a higher price. The Mexican firm said it secured funding and met other milestones Prestige insisted on.
Gordon Pedersen was indicted on criminal charges linked to posing as a physician to fraudulently promote and sell ingestible silver-based products as a cure for COVID-19 despite having no evidence his products could treat or cure the disease.